Novartis’ Itvisma (onasemnogene) has been approved by the US FDA to treat spinal muscular atrophy (SMA) in children aged two ...

Regeneron Pharmaceuticals’ Libtayo (cemiplimab) has received approval from the European Commission for the adjuvant treatment ...

Go behind the scenes of The participation equation – our call to put people, not just data, at the heart of clinical research ...

As the understanding of obesity continues to evolve, so too does the science, patient experience, and cross-sector ...